-
Mashup Score: 0Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials - Michael Morris - 54 minute(s) ago
Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of Pluvicto (lutetium PSMA-617) in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto’s approval by demonstrating significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) for patients with PSMA-positive disease. Dr. Morris…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0An International Multi-Institutional Validation Study of the Algorithm for Prostate Cancer Detection and Gleason Grading - Beyond the Abstract - 1 hour(s) ago
HALO Prostate AI, prostate cancer, Diagnosing prostate cancer, HALO AP digital pathology, Gleason Grading, Prostate Cancer Detection and Gleason Grading, prostate core needle biopsies.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
MRI-Based Radiomics Analysis, MRI-Based Radiomics Analysis of Levator Ani Muscle, Levator Ani Muscle for Predicting Urine Incontinence, Robot-Assisted Radical Prostatectomy (RARP), Urine Incontinence, Urine Incontinence after Robot-Assisted Radical Prostatectomy.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
bladder cancer, Circulating Tumor DNA (ctDNA), Residual Disease Detection, imvigor010 study, immunotherapy, adjuvant therapy, urine tumor DNA markers, treatment of invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon - 4 hour(s) ago
Pedro Barata and María Bourlon discuss the CheckMate 9ER trial’s 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo https://t.co/lRDatnvYxz
-
-
Mashup Score: 3Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath - 20 hour(s) ago
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores the importance of collaboration between urology and medical oncology, particularly in administering triplet therapy. Dr. Hafron highlights the evolution of their partnership, emphasizing shared knowledge and…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian - 20 hour(s) ago
Jeffrey Tosoian presents a new tool in prostate cancer diagnosis with the development and validation of an 18-gene urine test designed to identify clinically significant prostate cancer published in JAMA Oncology. This research, supported by the Prostate Cancer Foundation (PCF) and the NCI Early Detection Research Network, introduces a novel approach to enhancing the accuracy of prostate cancer…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8Key Takeaways from the UCLA/UCSF PSMA PET and RLT: Present and Future Conference - Jeremie Calais - 22 hour(s) ago
Jeremie Calais joins Phillip Koo on UroToday to discuss the first annual PSMA conference hosted by UCLA and UCSF in partnership with PCF. The conference highlights include discussions on PSMA theranostics in prostate cancer and aimed to leverage early experiences and global collaborations in PSMA clinical use. It featured a multidisciplinary panel of experts from around the world, focusing on…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Metastatic Hormone-sensitive Prostate Cancer Treatment, Docetaxel, Novel Hormonal Therapy (NHT), enzalutamide, apalutamide, abiraterone, androgen deprivation therapy (ADT).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Lutetium-177 PSMA radioligand therapy for advanced #ProstateCancer: Reviewing the pivotal #VISION and #TheraP trials. @morr316 @MSKCancerCenter joins @Daniel_J_George @DukeCancer in this discussion on UroToday > https://t.co/XWV5OQPjQ7 https://t.co/hNAefdyQuQ